The design of this registered study aims to evaluate the efficacy and safety of Paxlovid in the treatment of hospitalized COVID-19 patients, and to explore factors related to the efficacy and safety of Paxlovid.
Study Type
OBSERVATIONAL
Enrollment
488
Patients treated with PAXLOVID within 5 days of being diagnosed with covid-19 will be included in this group. Patients treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
Disease progression rates
The proportion of patients who experienced any of the following events within 28 days after being diagnosed with COVID-19, including all-cause mortality, requiring invasive mechanical ventilation, or being admitted to the intensive care unit.
Time frame: up to 28 days
all-cause deaths rates
The proportion of patients who experienced all-cause mortality within 28 days after being diagnosed with COVID-19.
Time frame: up to 28 days
rehospitalization event rates
The proportion of patients who experienced a rehospitalization event within 28 days after being diagnosed with COVID-19
Time frame: up to 28 days
COVID-19 repositive event rates
The proportion of patients who experienced a COVID-19 repositive event within 28 days after being diagnosed with COVID-19
Time frame: up to 28 days
adverse drug reaction event
The proportion of patients who experienced any adverse drug reaction events within 28 days after being diagnosed with COVID-19.
Time frame: up to 28 days
thromboembolic event rates
The proportion of patients who experienced thromboembolic events, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, within 28 days after being diagnosed with COVID-19.
Time frame: up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Patients treated with PAXLOVID outside of the initial 5 days after being diagnosed with covid-19 will be included in this group.